<DOC>
	<DOC>NCT00562055</DOC>
	<brief_summary>This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.</brief_summary>
	<brief_title>Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>1. Diagnosis of Attention Deficit Hyperactivity Disorder according to DSMIV criteria. 2. Score of 24 or higher on the Adult ADHD Investigator Symptom Rating Scale 3. Score of 4 or higher on the Clinician Global Impression Severity scale 1. Significant comorbid psychiatric diagnoses 2. Significant risk of suicidal or violent behavior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>